Back to search

Article

Primate-Specific LINC03040 Drives MASH Fibrosis via a Myeloid-Dependent Immuno-Metabolic Axis

2026-02-09

Abstract excerpt

<title>Abstract</title> <p> Background While the recent approval of resmetirom marks a historic milestone in MASH therapy, the effective reversal of established cirrhosis (F4) remains a major unmet clinical need. A critical bottleneck in developing anti-fibrotic drugs for this advanced stage is the profound translational gap between murine models and human immunopathology, particularly regarding species-specifi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1c682606-a086-5fca-90dc-6d6daca15fd5
DOI
10.21203/rs.3.rs-8780157/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Primate-Specific LINC03040 Drives MASH Fibrosis via a Myeloid-Dependent Immuno-Metabolic AxisDOI 10.21203/rs.3.rs-8780157/v1
Select a neighboring publication to make it the new centre.